Compare XPRO & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | XPRO | AGIO |
|---|---|---|
| Founded | 1938 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.0B |
| IPO Year | 2013 | 2013 |
| Metric | XPRO | AGIO |
|---|---|---|
| Price | $18.13 | $24.90 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 8 |
| Target Price | $16.00 | ★ $38.88 |
| AVG Volume (30 Days) | 996.8K | ★ 1.3M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.45 | N/A |
| Revenue | ★ $522,493,000.00 | $43,011,000.00 |
| Revenue This Year | $1.86 | $76.75 |
| Revenue Next Year | $4.70 | $170.73 |
| P/E Ratio | $39.61 | ★ N/A |
| Revenue Growth | ★ 14.89 | N/A |
| 52 Week Low | $7.57 | $22.24 |
| 52 Week High | $18.73 | $46.00 |
| Indicator | XPRO | AGIO |
|---|---|---|
| Relative Strength Index (RSI) | 62.52 | 31.14 |
| Support Level | $15.39 | $24.16 |
| Resistance Level | $18.60 | $29.69 |
| Average True Range (ATR) | 0.57 | 1.16 |
| MACD | 0.17 | -1.11 |
| Stochastic Oscillator | 97.33 | 4.00 |
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA); and Asia-Pacific (APAC). The majority of its revenue is derived from the North and Latin America (NLA) segment.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.